# Opioids

**Ohio law requires prescribers to request and review an OARRS report before initially prescribing or personally furnishing any controlled substance, such as an opioid analgesic or a benzodiazepine, and gabapentin**

## Length of Authorizations

For the course of therapy, up to 180 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Additional Criteria

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **7 days** of at least **two unrelated** preferred drugs
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Short-Acting for New Starts

Additional SHORT-ACTING Opioids Criteria for New Starts

-   The system defines a “new start” as having no opioid claims in the previous 90 days
-   **Initial short-acting requests** can be authorized up to 90 days
    -   Length of authorization is dependent on indication, previous patient utilization, and requested length of therapy (could be more restrictive)
    -   To exceed acute opioid limits, documentation of the following must be provided:
        -   Diagnosis code which must be for somatic type pain
        -   Prescriber attestation that the benefits and risks of opioid therapy has been discussed with patient
    -   Exemptions to the additional criteria:
        -   Patients receiving short-acting opioids for active cancer treatment, palliative care, and end-of-life/hospice care, sickle cell, severe burn, traumatic crushing of tissue, amputation, major orthopedic surgery
        -   Prescriber attestation that patient is not opioid naïve (i.e., new to Medicaid or was on higher dose in hospital)

### Long-Acting

Additional LONG-ACTING Opioids Criteria

-   **Initial long-acting requests** can be authorized up to 90 days
    -   Documentation of the following must be provided:
        -   Request is a daily dose equivalent of ≤ 80 MED
        -   Inadequate clinical response to both non-opioid pharmacologic and non-pharmacologic treatments
        -   History of short-acting opioids for ≥ 60 days
        -   Treatment plan including risk assessment, substance abuse history, concurrent therapies, and requirements for random urine screenings (baseline urine drug tests must be submitted)
        -   Pain and function scores at each visit
        -   Opioid contract required to be in place and submitted with PA form
    -   Exemptions to the additional criteria:
        -   Patients receiving long-acting opioids for catastrophic injury or cancer pain
-   **Subsequent long-acting requests** can be authorized up to 180 days
    -   Documentation of the following must be provided:
        -   Current treatment plan
        -   Demonstrated adherence to treatment plan through progress notes, including pain and function scores, random urine screenings results reviewed, concerns addressed, and no serious adverse outcomes observed
-   **Dose escalation requests** can be authorized up to 180 days
    -   Documentation of the following must be provided:
        -   Prescriber attestation that dose escalation is likely to result in improved function and pain control
        -   Requests for a daily dose \>100 MED must be prescribed by pain specialist or anesthesiologist consultation

### Transmucosal Fentanyl 


Additional Transmucosal Fentanyl Criteria

-   Must be prescribed by an oncologist, pain specialist, or hospice/palliative prescriber
-   Must be concurrently taking a long-acting opioid at a therapeutic dose of any of the following for at least **7 days** without adequate pain relief:

|                                  |                                      |
| -------------------------------- | ------------------------------------ |
| ≥ 60 mg oral morphine/day        | ≥ 8 mg oral hydromorphone/day        |
| ≥ 25 mcg/hr transdermal fentanyl | ≥ 25 mg oral oxymorphone/day         |
| ≥ 30 mg oral oxycodone/day       | Equianalgesic dose of another opioid |

**QL** – Transmucosal Fentanyl: 4 doses per day

Effective July 1, 2018, patients with short acting opioid therapy will be limited to 30 MED per prescription and a maximum of 7 days per prescription. Prior authorization will be required to exceed these limits

## Formulary

Analgesic Agents: Opioids

### Preferred

| Preferred                                    |      |
| :------------------------------------------- | ---: |
| Acetaminophen/Codeine QL                     |      |
| Butalbital/Acetaminophen/Caffeine/Codeine QL |      |
| Butalbital/Aspirin/Caffeine/Codeine QL       |      |
| Butorphanol QL                               |      |
| Butrans BvG PA QL                            |      |
| Codeine QL                                   |      |
| Hydrocodone/Acetaminophen QL                 |      |
| Hydromorphone IR QL                          |      |
| Morphine ER Tab PA QL                        |      |
| Morphine Sol QL                              |      |
| Morphine Tab QL                              |      |
| Oxycodone Cap QL                             |      |
| Oxycodone Sol QL                             |      |
| Oxycodone Tab QL                             |      |
| Oxycodone/Acetaminophen QL                   |      |
| Tramadol QL                                  |      |
| Tramadol/Acetaminophen QL                    |      |

### Non-Preferred

| Non-Preferred                                              |      |
| :--------------------------------------------------------- | ---: |
| Acetaminophen/Caffeine/Dihydrocodeine QL                   |      |
| Belbuca QL                                                 |      |
| Benzhydrocodone/Acetaminophen QL                           |      |
| Buprenorphine TD Patch Weekly QL                           |      |
| Butalbital/Acetaminophen/Caffeine/Codeine 50-300-40-30mgQL |      |
| Dsuvia QL                                                  |      |
| Fentanyl QL                                                |      |
| Hydrocodone Bitartrate ER 12HR CapQL                       |      |
| Hydrocodone Bitartrate ER 24HR TabQL                       |      |
| Hydrocodone/Acetaminophen 5-300, 7.5-300, 10-300mg QL      |      |
| Hydrocodone/Ibuprofen QL                                   |      |
| Hydromorphone ER QL                                        |      |
| Levorphanol QL                                             |      |
| Meperidine QL                                              |      |
| Methadone QL                                               |      |
| Morphine ER 24HR Cap QL                                    |      |
| Nucynta, ER QL                                             |      |
| Oxaydo QL                                                  |      |
| Oxycodone ER QL                                            |      |
| Oxycodone/Ibuprofen QL                                     |      |
| Oxymorphone, ER QL                                         |      |
| Pentazocine/Naloxone QL                                    |      |
| Seglentis QL                                               |      |
| Tramadol ER QL                                             |      |
| Tramadol Sol QL                                            |      |
| Xtampza ER QL                                              |      |

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=7)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220701_UPDL_FINAL.pdf#page=6)